Business context and reporting period
The supplied filing is Novus Therapeutics, Inc.’s Form 10-Q for the quarter ended September 30, 2020, not a filing under the name Eledon Pharmaceuticals, Inc. Novus acquired Anelixis Therapeutics on September 14, 2020, shifting its focus toward AT-1501, an anti-CD40L antibody in development for transplantation, autoimmune disease and ALS. Financial statements are unaudited; dollar amounts below are in millions unless stated otherwise.
Financial performance and position
| Metric | Q3 2020 / September 30, 2020 | Comparable period / prior year-end |
|---|---|---|
| Revenue | None reported in Novus’s statements of operations | None reported in Novus’s statements of operations |
| Research and development expense | $0.615 | $1.509 in Q3 2019 |
| General and administrative expense | $3.731 | $1.411 in Q3 2019 |
| Restructuring expense | $1.802 | None in Q3 2019 |
| Net loss | $6.144; $5.51 per share | $2.893; $4.01 per share in Q3 2019 |
| Cash and cash equivalents | $114.464 | $8.791 at December 31, 2019 |
| Working capital | $109.0 | Not stated for the comparable prior-year period |
| Total liabilities | $6.130 | $1.466 at December 31, 2019 |
| Debt | No outstanding debt reported |
For the nine months ended September 30, 2020, net loss was $16.907 versus $11.867 in 2019. Operating expenses were $12.117 versus $11.884; the 2020 period included $2.292 of restructuring expense and $4.829 of warrant-inducement expense in other expense. No profit or positive operating margin was reported.
Nine-month operating cash use was $5.779, compared with $11.834 in 2019. Investing cash inflow was $11.035, comprising cash acquired with Anelixis. Financing cash inflow was $100.417, including $95.226 net proceeds from preferred-stock financing and $5.191 net proceeds from warrant exercises. Cash increased by $105.673 over the period.
Material changes versus the prior comparable period
- Q3 net loss increased to $6.144 from $2.893, as higher G&A and restructuring costs more than offset lower R&D spending. G&A included approximately $2.2 million of Anelixis acquisition costs.
- Nine-month R&D fell 54% to $3.095, primarily following suspension of legacy OP0201 development after its Phase 2a trial missed primary efficacy endpoints. Management expects R&D expense to rise as AT-1501 development advances.
- The Anelixis acquisition added $32.386 million of in-process R&D and $44.466 million of goodwill; the purchase-price allocation was preliminary. Anelixis results were integrated, so the filing says post-acquisition results cannot practically be separated.
- September financing substantially strengthened cash, but included $164.949 million of Series X1 preferred stock classified outside stockholders’ equity.
Outlook, risks and unusual items
- Management stated that cash resources were sufficient for anticipated needs through at least 12 months from issuance of the statements. The company nevertheless expects continuing losses and says further funding may be needed to develop its candidates.
- Series X1 preferred-stock conversion requires stockholder approval. If approval is not obtained by March 13, 2021, holders may have cash-settlement rights; the filing warns that exercise could materially worsen liquidity and raise substantial doubt about the company’s ability to continue as a going concern. The company considered approval probable.
- Novus initiated a Phase 2 open-label ALS study of AT-1501 on October 27, 2020, after quarter-end. AT-1501 had completed a Phase 1 study; the filing describes it as well tolerated in that study, but it remains an early-stage candidate.
- The June workforce reduction and subsequent separation-related charges totaled $2.292 million for the nine months; $0.803 million remained accrued at quarter-end. The CEO resigned effective September 4, 2020.
- On October 5, 2020, Novus effected an 1-for-18 reverse stock split. Nasdaq notified the company on October 19 that it had regained minimum-bid-price compliance.
- The company cites clinical, regulatory, manufacturing, financing, patient-enrollment, COVID-19, competition and intellectual-property risks. The Tokai shareholder lawsuit was dismissed in October 2020; the plaintiff filed an appeal in November.
Most important facts to verify
- Confirm the issuer identity: the provided filing is for Novus Therapeutics, Inc., despite the request naming Eledon Pharmaceuticals, Inc.
- Check the status and terms of stockholder approval, conversion and cash-settlement rights for Series X1 preferred stock, including the contingent additional $9 million financing.
- Review updated cash runway, spending plans and financing needs as AT-1501 trials progress.
- Track clinical-trial progress and safety data for AT-1501, and any decision on the suspended OP0201 program.
- Verify the final purchase-price allocation for Anelixis and subsequent treatment of acquired goodwill and in-process R&D.